摘要:
The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyzes. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry.
摘要:
The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyses. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry.
摘要:
The present invention relates to beta-glucosidase that is mutated to have enhanced activity, and a method for producing bioethanol using the same. More particularly, the present invention relates to a polynucleotide encoding beta-glucosidase that is mutated to have enhanced activity, beta-glucosidase expressed from the polynucleotide, an expression vector including the polynucleotide, a transformant that is transformed with the expression vector, a method for producing the mutated beta-glucosidase using the transformant, and a method for producing bioethanol using the transformant. The mutant beta-glucosidase of the present invention increases production of glucose much more than the conventional beta-glucosidase, and thus it can be widely used for economic production of bioethanol.
摘要:
The present invention relates to a method for producing hEGF (human epidermal growth factor) which has the same activity as the wild form, in high concentration and with a high degree of purity. More specifically, the invention relates to an hEGF expression vector comprising a nucleic acid sequence coding for the polypeptide of sequence number 14; a host cell in which the expression vector has been genetically transformed; and a method for producing hEGF, comprising a step in which the expression vector is created and is genetically transformed in yeast from which the KEX1 gene is lacking. Using the method of the present invention, it is possible to produce a large volume of human derived EGF which has the same size and activity as human derived EGF, and this EGF can be used in various ways such as in medicine and cosmetics.
摘要:
The present invention relates to a method for producing hEGF (human epidermal growth factor) which has the same activity as the wild form, in high concentration and with a high degree of purity. More specifically, the invention relates to an hEGF expression vector comprising a nucleic acid sequence coding for the polypeptide of sequence number 14; a host cell in which the expression vector has been genetically transformed; and a method for producing hEGF, comprising a step in which the expression vector is created and is genetically transformed in yeast from which the KEX1 gene is lacking. Using the method of the present invention, it is possible to produce a large volume of human derived EGF which has the same size and activity as human derived EGF, and this EGF can be used in various ways such as in medicine and cosmetics.